research Unexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights
Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
Search
for
Sort by
Research
120-150 / 789 results 
research New Treatments for Hair Loss
Several new treatments for different types of hair loss show promise in improving patient quality of life.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies
Animal models have helped understand hair loss from alopecia areata and find new treatments.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Topical Janus kinase inhibitors: A review of applications in dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research Genome-Wide Association Study of Alopecia Areata in Taiwan: The Conflict Between Individuals and Hair Follicles
Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.
research An Overview about Alopecia Areata Etiopathogenesis, Diagnosis, and Management: Review Article
Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
research The role of lymphocytes in the development and treatment of alopecia areata
Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Transcriptional Profiling in Rat Hair Follicles following Simulated Blast Insult: A New Diagnostic Tool for Traumatic Brain Injury
Hair follicles can help diagnose traumatic brain injury quickly and non-invasively.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
Personalized treatments for hair loss focus on specific genetic and biological pathways.
research A Bibliometric Analysis of Alopecia Areata Literature over the Past 50 Years.
More research is needed on alopecia areata treatments and its psychological effects.
research Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
New treatments for Alopecia Areata show promise but need to be more effective and affordable.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
research Pharmacological Treatment of Alopecia
Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
research MSC-EVs and UCB-EVs promote skin wound healing and spatial transcriptome analysis
MSC-EVs and UCB-EVs improve skin wound healing and reduce scarring.
research Emerging treatments in alopecia
New alopecia treatments aim for better results and fewer side effects.
research Cutaneous transcriptome analysis in NIH hairless mice
Key genes linked to hair growth and cancer were identified in hairless mice.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research INVESTIGATING THE MECHANISMS UNDERLYING THE PATHOGENESIS OF ALOPECIA AREATA
Alopecia areata may be treated by using EGCG to balance immune cells and reduce inflammation.
research Generating detailed intercellular communication patterns in psoriasis at the single-cell level using social networking, pattern recognition, and manifold learning methods to optimize treatment strategies
New insights into cell communication in psoriasis suggest innovative drug treatments.
research Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
Baricitinib reduces inflammation and improves cell health in premature aging cells.
research The JAK/STAT signaling pathway: from bench to clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.